SRPT
Sarepta TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-22
+
Peers tracked
11
U.S. public peers
Grade Position
Above peers
vs peer average
SRPT vs peer average
86/100
SRPT vs. peer average (A vs. C)
Grade spread
B 2 · C 5 · D 3 · F 1
Graded peers loaded
Coverage
11 graded
100% of tracked
Peer overview
RARE is the first available peer comparator.
Ultragenyx — rare-disease specialist with comparable orphan-program commercialization and regulatory-readout risk profile.
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
SRPT
Sarepta Therapeutics
RARE
Ultragenyx Pharmaceutical
Grade
A
C
Momentum
22
83
Value
52
41
Sentiment
100
39
Setup Bias
Net —
-
Market Cap
-
-
Posture
Constructive
Mixed
Grade position vs RARE
SRPT / RARE
Grade Position
Above peers
SRPT vs. peer average (A vs. C)
86/100
Momentum
22
RAREValue
52
SRPTSentiment
100
SRPTRotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs SRPT
RARE is the first peer returned for this comparison set.